Cogent Biosciences, Inc. (COGT)
| Market Cap | 1.72B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -269.50M |
| Shares Out | 139.49M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,025,852 |
| Open | 12.75 |
| Previous Close | 12.49 |
| Day's Range | 11.93 - 12.97 |
| 52-Week Range | 3.72 - 12.97 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 20.25 (+64.63%) |
| Earnings Date | Aug 5, 2025 |
About COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and sel... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price target is $20.25, which is an increase of 64.63% from the latest price.
News
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results
I have upgraded Cogent Biosciences, Inc. to Strong Buy after positive SUMMIT trial data for bezuclastinib in non-advanced systemic mastocytosis patients. COGT plans to submit an NDA for bezuclastinib ...
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder.
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to ...
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
Facility provides additional funding for next steps of the Company's growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year, begi...
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Reports First Quarter 2025 Financial Results
Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected...
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pi...
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on tr...
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK tri...
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its mai...
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with me...
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Cogent Biosciences Reports First Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
• UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected b...